An inflammatory bowel disease–risk variant in \textit{INAVA} decreases pattern recognition receptor–induced outcomes

Jie Yan, Matija Hedl, and Clara Abraham

Department of Medicine, Yale University, New Haven, Connecticut, USA.

Introduction

Inflammatory bowel disease (IBD) is characterized by dysregulation in both cytokines and responses to intestinal microbes, and proper regulation of pattern recognition receptor (PRR) signaling is critical for intestinal immune homeostasis. Altered functions for the IBD risk locus containing rs7554511, which encompasses the \textit{C1orf106} gene (recently named \textit{INAVA}), and roles for the protein encoded by the \textit{INAVA} gene are unknown. Here, we investigated the role of \textit{INAVA} and \textit{INAVA} genotype in regulating PRR-initiated outcomes in primary human cells. Both peripheral and intestinal myeloid cells expressed \textit{INAVA}. Upon PRR stimulation, \textit{INAVA} was required for optimal MAPK and NF-κB activation, cytokine secretion, and intracellular bacterial clearance. \textit{INAVA} recruited 14–3-3τ, thereby contributing to recruitment of a signaling complex that amplified downstream signals and cytokines. Further, \textit{INAVA} enhanced bacterial clearance by regulating reactive oxygen, reactive nitrogen, and autophagy pathways. Macrophages from rs7554511 C risk carriers expressed lower levels of \textit{INAVA} RNA and protein. Lower expression was attributed in part to decreased transcription mediated directly by the intronic region containing the rs7554511 C variant. In rs7554511 C risk carrier macrophages, lower \textit{INAVA} expression led to decreased PRR-induced activation of MAPK and NF-κB pathways, cytokines, and bacterial clearance pathways. Thus, IBD-associated polymorphisms in \textit{INAVA} modulate PRR-initiated signaling, cytokines, and intracellular bacterial clearance, likely contributing to intestinal immune homeostasis.

Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: January 4, 2016; Accepted: February 16, 2017.
https://doi.org/10.1172/JCI86282.
the protein in regulating PRR-initiated outcomes, as well as establishing loss-of-function consequences for the IBD-associated risk variant in this gene.

**Results**

**MDMs from rs7554511 C risk carriers in INAVIDA demonstrate decreased PRR-induced secretion of cytokines.** PRR-initiated outcomes, including cytokine secretion, in myeloid-derived cells are important in IBD pathophysiology (2). As the rs7554511 polymorphism in INAVIDA is associated with IBD, we questioned if PRR-initiated cytokine secretion from primary human monocyte-derived cells is modulated by INAVIDA genotype. Given the association of NOD2 with Crohn’s disease (1), we initially utilized muramyl dipeptide (MDP), the component of peptidoglycan that specifically activates NOD2 (17–20), to treat MDMs. We examined TNF secretion, given its role in IBD (1). MDMs from rs7554511 C risk carriers secreted less TNF upon NOD2 stimulation compared with AA carriers across a range of MDP doses (Figure 1). We observed similar regulation of yet another proinflammatory cytokine, IL-1β (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI86282DS1). Similar results were observed with the antiinflammatory cytokine IL-10 (Supplemental Figure 1B), such that the polymorphism regulates both pro- and antiinflammatory cytokines. Microbial products activate multiple PRRs. Upon dose-dependent stimulation of multiple TLRs, relative to AA carriers, MDMs from rs7554511 C risk carriers secreted less TNF, IL-1β, and IL-10 (Figure 1 and Supplemental Figure 1). We further stratified on multiple polymorphisms within the rs7554511 region and found that the rs7554511 variant (along with those variants in linkage disequilibrium [LD] with rs7554511) was associated with the most significant modulation of NOD2-induced cytokines (Supplemental Figure 2). Therefore, relative to rs7554511 AA carriers, MDMs from C risk carriers exhibit lower cytokine secretion upon stimulation of a broad range of PRRs.

**INAVIDA is required for optimal PRR-induced cytokine secretion from MDMs.** Rs7554511 is located in an intronic region of the INAVIDA gene. However, given the lack of prior reports on this gene, and the presence of other genes in the region (Supplemental Figure 3A), we considered that any one or all of the genes may be accounting for the genotype-dependent effects observed. We therefore first effectively knocked down each of the genes within a ~500-kb distance from rs7554511 in human MDMs (Supplemental Figure 3B), and examined which of the candidate genes regulated NOD2-induced cytokines. INAVIDA knockdown led to a significant decrease in NOD2-induced proinflammatory and antiinflammatory cytokines (Figure 2A), whereas knockdown of the other genes in the region did not (Supplemental Figure 3C). Knocking down INAVIDA in MDMs did not affect cell viability (Supplemental Figure 4A), and cells remained responsive to alternative stimuli to the dectin receptor (Supplemental Figure 4B), a receptor that responds to fungal products and initiates distinct proximal signaling pathways (21). INAVIDA regulated NOD2 responses over a wide range of MDP doses (Supplemental Figure 4C). The differential effect with INAVIDA knockdown was most visible at the highest MDP dose (Supplemental Figure 4C), such that we will use this dose in the studies that ensue. NOD2-induced cytokines were decreased upon INAVIDA knockdown with 3 additional siRNAs (Supplemental Figure 4D and E). Furthermore, knockdown of INAVIDA led to decreased cytokine secretion upon stimulation of a broad range of PRRs (Figure 2B). Consistently, INAVIDA regulated both MyD88-dependent and -independent outcomes upon stimulation of TLR4 (Supplemental Figure 5). Therefore, INAVIDA is required for optimal responses upon stimulation of a broad range of PRRs.

**INAVIDA expression is induced in human MDMs with PRR stimulation and INAVIDA is highly expressed in intestinal myeloid-derived cells.** Given the intronic location of rs7554511, we considered that INAVIDA expression might be modulated in an rs7554511 genotype-specific manner. We therefore first examined if INAVIDA expression was induced with NOD2 stimulation. Expression of INAVIDA mRNA
INAVA is required for optimal secretion of cytokines in MDMs upon stimulation through a broad range of PRRs. Human MDMs (n = 4) were transfected with scrambled or INAVA siRNA. Cells were treated with (A) 100 μg/ml MDP or (B) 10 μg/ml Pam,Cys (recognized by TLR2), 100 μg/ml poly:C (recognized by TLR3), 0.1 μg/ml lipid A (recognized by TLR4), 5 ng/ml flagellin (recognized by TLR5), 1 μg/ml CL097 (recognized by TLR7), or 10 μg/ml CpG DNA (recognized by TLR9) for 24 hours. Mean cytokine secretion ± SEM is shown. Similar results were observed in an additional n = 16 for A and n = 8 for B. Tx, treatment; Scr, scrambled. *P < 0.01; †P < 0.001; ‡P < 1 × 10⁻⁴; §P < 1 × 10⁻⁵; determined by 2-tailed Student’s t test.

MDMs from rs7554511 C risk carriers demonstrate lower INAVA expression. We next questioned if INAVA expression was regulated in an rs7554511 genotype–dependent manner. Consistent with the lower cytokine secretion from MDMs of rs7554511 CC risk carriers, MDMs from rs7554511 CC carriers expressed less INAVA mRNA than AA carriers at baseline; this differential was further enhanced upon NOD2 stimulation (Figure 4A) and was observed in both INAVA transcripts (Figure 4A). The ratio of the transcripts was not significantly different with rs7554511 genotype (data not shown). MDMs from rs7554511 heterozygote carriers generally demonstrated an intermediate level of INAVA mRNA expression (Figure 4A). Lower INAVA expression was also observed at the protein level in rs7554511 CC risk carriers (Figure 4B). Of note, for the genes in the region that did not regulate NOD2-induced cytokines as per Supplemental Figure 3C, their expression was also not modulated in a genotype-dependent manner in MDMs (Supplemental Figure 7). Therefore, INAVA expression increases with NOD2 stimulation, and MDMs from rs7554511 C risk carriers express less INAVA relative to AA carriers.

Modulation in INAVA expression levels by the rs7554511 variant accounts for the INAVA-dependent PRR-induced cytokine secretion. We sought to clearly establish that modulation in INAVA expression levels accounted for the INAVA genotype–dependent regulation of PRR-induced cytokines. Therefore, we progressively reduced the levels of INAVA in MDMs from high-expressing rs7554511 AA carriers to the levels observed in CC carriers, as well as beyond these levels in accordance with the degree of protein reduction in the knockdown studies above (Supplemental Figure 8A). With reduction of INAVA expression in AA carrier MDMs to the levels observed in CC carrier MDMs, cells demonstrated similar levels of NOD2-induced cytokine secretion compared with rs7554511 CC carrier MDMs (Supplemental Figure 8B). Interestingly, in examining the relationship between INAVA expression and NOD2-induced cytokines over a broader range of INAVA concentrations, there was a clear threshold of INAVA expression at which NOD2-induced cytokines more rapidly decreased (Supplemental Figure 8C). We then conducted the complementary studies wherein we increased INAVA expression in rs7554511 CC risk–carrier MDMs to the levels observed in rs7554511 AA carrier MDMs (Supplemental Figure 8B). This resulted in similar levels of cytokine secretion compared with AA carrier MDMs (Supplemental Figure 9B). Therefore, the modulation in INAVA expression levels associated with the intronic rs7554511 variant in the INAVA region accounts for the regulation in the INAVA-dependent outcomes observed.
The INAVA rs7554511 variant alters intron-driven transcription. As INAVA expression modulation accounted for the rs7554511 genotype–dependent effects on PRR-induced cytokines, we next sought to understand the mechanisms regulating INAVA expression, and which of these mechanisms might account for the rs7554511-modulated INAVA expression regulation. Gene expression can be dramatically modulated by miRNA binding, and there is a putative miRNA-24 binding site in the 3′ UTR of INAVA (Supplemental Figure 10A). Upon miRNA-24 mimic overexpression in MDMs, INAVA expression levels decreased, while with a miRNA-24 hairpin inhibitor, INAVA expression levels increased (Supplemental Figure 10B). Consistent with INAVA expression levels regulating NOD2-induced cytokines, miRNA-24 mimic overexpression reduced NOD2-induced cytokines, while the miRNA-24 hairpin inhibitor increased NOD2-induced cytokines (Supplemental Figure 10C). To more clearly examine the putative region within the 3′ UTR of INAVA containing miRNA-24, and to determine if there were genetic variants regulating miRNA-24–modulated INAVA expression, we subcloned a portion of the 3′ UTR region of INAVA containing the predicted miRNA-24 binding site into a luciferase construct driven by a PGK promoter. When this INAVA 3′ UTR miRNA-24 region construct was expressed in HEK293 cells along with miRNA-24, luciferase expression from the INAVA 3′ UTR was reduced, whereas with the miRNA-24 hairpin inhibitor, luciferase expression was increased (Supplemental Figure 10D). Luciferase activity in a construct in which the consensus nucleotides of the miRNA-24 binding site in INAVA were mutated (as per Supplemental Figure 10A) was not regulated with miRNA-24 mimic or hairpin inhibitor (Supplemental Figure 10D), thereby establishing the specificity of the miRNA-24 regulation. Per dbSNP there are 2 single nucleotide polymorphisms (SNPs) at rs1048978 and rs558221123 contained within the miRNA-24 binding region. Mutating these sites to the respective derived variant did not alter luciferase regulation relative to the ancestral variant (Supplemental Figure 10D). Mutating a third SNP (rs35084944) described in dbSNP just outside of the predicted miRNA-24 region also did not alter the pattern of luciferase regulation from the INAVA 3′ UTR gene region examined. Furthermore, these SNPs were not in LD with the rs7554511 polymorphism. Therefore, while miRNA-24 binding in the 3′ UTR of INAVA decreases INAVA expression, the identified SNPs in this region neither modulate this regulation nor are in LD with the INAVA IBD-associated rs7554511 variant.

We next questioned if the intronic region where rs7554511 is located regulates INAVA expression, and if so, if this expression is regulated in a rs7554511 genotype–dependent manner. We identified various transcription factor consensus sites that directly overlap with the rs7554511 variant in intron 6 (Supplemental Figure 11A). Through knockdown of endogenous transcription factors in MDMs (Supplemental Figure 11B), we identified that TATA box-binding protein (TBP) and homeobox A5 (HOXA5) were required for both optimal baseline and NOD2-induced INAVA RNA expres-
sion, whereas NKX2-5 was not (Supplemental Figure 11C). As TBP contributed to a greater degree to NOD2-induced INAVA RNA expression, we focused on TBP and included NKX2-5 as a negative control. Similar to mRNA regulation, TBP regulated baseline and NOD2-induced INAVA protein expression in MDMs (Supplemental Figure 11D). Consistent with these findings, TBP was required for NOD2-induced cytokines, whereas NKX2-5 was not (Supplemental Figure 11E).

As TBP might be regulating INAVA expression through locations in INAVA in addition to the putative binding site in intron 6, we subcloned intron 6 (842 bp) containing the rs7554511 A variant upstream of a luciferase reporter construct to determine potential regulation by TBP specifically in the intron 6 region. Upon transfection of this construct into HEK293 cells, we observed INAVA intron 6–driven luciferase expression and this expression was increased with MDP treatment (Figure 5A). Through knockdown of TBP (Supplemental Figure 11F), we found that TBP was required for optimal INAVA intron 6–driven luciferase expression, both at baseline and upon MDP treatment (Figure 5A). Given the decreased INAVA expression in MDMs from rs7554511 C risk carriers, we next questioned if intron 6 containing the rs7554511 C risk variant demonstrated less transcriptional activity than did the rs7554511 A variant, and we found this to be the case (Figure 5B).

Importantly, expressing TBP in HEK293 cells transfected with the intron 6 rs7554511 A variant significantly enhanced NOD2-induced transcription (Figure 5C). Taken together, these results demonstrate that the intron 6 rs7554511 A variant has increased transcriptional activity relative to the C variant, with TBP being one transcription factor mediating the increased transcriptional activity.

MDMs from rs7554511 C risk carriers in INAVA demonstrate decreased PRR-induced MAPK and NF-κB activation. We next questioned the mechanisms through which INAVA regulates PRR-initiated cytokines. We first examined the signaling pathways regulated by INAVA upon NOD2 stimulation. Activation of MAPK and NF-κB pathways is critical for NOD2-induced cytokines (6, 7, 19, 24–26). Activation of the MAPKs ERK, p38, and JNK (Figure 6A), and the NF-κB pathway (Figure 6B) were impaired upon NOD2 stimulation of MDMs in which INAVA was knocked down. Consistently, binding of transcription factors to cytokine promoters downstream of these pathways, including c-Jun, c-Fos, and NF-κBp65, was decreased upon INAVA knockdown in MDMs with NOD2 stimulation (Supplemental Figure 12). Moreover, signaling downstream of multiple PRRs was decreased with INAVA knockdown (Supplemental Figure 13). Finally, we questioned if the INAVA-dependent signaling pathways observed with NOD2 stimulation were regulated in an rs7554511 genotype–dependent manner; we focused on rs7554511 AA and CC carriers for these studies. Consistent with the lower INAVA expression (Figure 4), and decreased cytokine secretion (Figure 1), NOD2-induced activation of the MAPK (Figure 6C) and NF-κB (Figure 6D) pathways was decreased in MDMs from rs7554511 CC carriers relative to AA carriers.

**INAVA translocates to the nucleus upon NOD2 stimulation.** To further define mechanisms for INAVA contributions to PRR-induced signaling, we considered the structural regions of INAVA that might, in turn, be regulating functional outcomes. We noted that there were 3 potential nuclear localization signals (NLSs) in
INAVA (Supplemental Figure 14A). We therefore first questioned if INAVA translocated to the nucleus upon NOD2 stimulation. We observed peak INAVA nuclear translocation 2 hours after MDP treatment of MDMs (Supplemental Figure 14B). To establish if the putative NLSs contributed to the nuclear translocation, and in turn, NOD2-induced signaling and cytokines, we generated INAVA mutants in which each of the 3 putative NLSs was mutated alone (mNLS), and in combination, and transfected these into HEK293 cells along with NOD2. Translocation of INAVA was only slightly decreased with transfection of INAVA mNLS1, mNLS2, or mNLS3 relative to WT INAVA upon NOD2 stimulation (Supplemental Figure 14C). NOD2-induced AP-1 and NF-κB activation (Supplemental Figure 14D) and IL-6 secretion (Supplemental Figure 14E) were not significantly altered with transfection of INAVA mNLS1, mNLS2, or mNLS3 relative to WT INAVA. However, mutation of all 3 NLSs in combination resulted in a failure of INAVA nuclear translocation upon NOD2 stimulation (Supplemental Figure 14C), and this was accompanied by a modest, albeit significant reduction in NOD2-induced AP-1 and NF-κB activation and IL-6 secretion (Supplemental Figure 14, D and E). We did not observe increased INAVA binding to cytokine promoters in MDMs upon NOD2 stimulation as assessed by ChIP (Supplemental Figure 14F). Therefore, although INAVA translocates to the nucleus upon NOD2 stimulation and this translocation requires the cooperation of 3 NLSs in INAVA, this nuclear translocation event contributes to NOD2-induced signaling and cytokines only to a minor degree.

INAVA associates with 14-3-3 and additional signaling molecules upon PRR stimulation. To further define the mechanisms through which INAVA regulates NOD2- and PRR-initiated signaling, we next considered cytoplasm-associated contributions for INAVA and questioned if INAVA could directly associate with NOD2 and RIP2, the adaptor molecule required for NOD2-initiated signaling. We found that this was the case (Figure 7A). We also found that IRAK1, which is required for proximal NOD2/RIP2-initiated signaling (20, 27), associated in a complex with INAVA (Figure 7A). We confirmed that NOD2, RIP2, and IRAK1 were required for the MDP-induced signaling (Supplemental Figure 15A) and cytokine secretion (Supplemental Figure 15B) observed in MDMs. We next considered additional structural regions of INAVA and how they, in turn, might regulate the ability of INAVA to assemble a signaling complex. We identified 3 putative 14-3-3 binding domains in INAVA (Figure 7B); 14-3-3 proteins can serve as scaffolding proteins that then recruit a diverse array of signaling proteins (28). While 14-3-3 proteins have been well described in regulating a variety of cell processes, including cell cycle progression and cancer (29, 30), relatively few studies have dissected their role in modulating signaling downstream of PRRs (31–34). The putative 14-3-3 binding domains in INAVA, in particular the serine residues mediating binding, are conserved across species (Figure 7B). In fact, the full INAVA protein has an identity ranging from 99.7% in mammals to 37% in zebrafish (Supplemental Figure 16A). Moreover, in examining a phylogenetic tree, the INAVA (CeforTP06) gene family arose early in bony fish evolution; the genes encoding FRMD4A, FRMD4B, and CCDC120 are potential paralogs of INAVA (Supplemental Figure 16B). Given the identified 14-3-3 binding regions in INAVA, we first examined if 14-3-3 is recruited to INAVA. We focused on 14-3-3α (also known as YWHAQ or 14-3-3 protein theta), given a report suggesting a role for this member in enhancing select measures downstream of TLR activation (34). We observed that there was a baseline association of 14-3-3α with INAVA under unstimulated conditions, and this association increased within 15 minutes of NOD2 stimulation in MDMs (Figure 7C). Of note is that 14-3-3α protein expression did not increase with NOD2 stimulation (Supplemental Figure 17A). 14-3-3 can recruit various signaling molecules, including activated MAPKs and NF-κB (28, 35), pathways we had observed to be modulated by INAVA upon PRR stimulation (Figure 6). We therefore examined if p-ERK, p-p38, and p-IκBα were recruited to INAVA upon NOD2 stimulation of MDMs, and we found this to be the case (Figure 7C). There was a baseline association of unphosphorylated ERK and p38 in a complex with INAVA, and the recruitment of these signaling molecules increased with NOD2 stimulation (Figure 7C). To further establish the role of 14-3-3α in INAVA modulation of NOD2 signaling, we effectively knocked down 14-3-3α (Supplemental Figure 17, B and C). We verified that 14-3-3α recruitment to INAVA was significantly attenuated under these conditions (Figure 7D). We then examined p-ERK recruitment as one of the signaling proteins we had identified to be recruited to INAVA. Recruitment of p-ERK to INAVA upon NOD2 stimulation was impaired upon 14-3-3α knockdown in MDMs (Figure 7D), thereby confirming the role of
14-3-3τ in the recruitment of p-ERK to INAVA. Consistently, both NOD2-induced ERK activation (Figure 7E) and cytokine secretion (Figure 7F) were decreased in MDMs upon 14-3-3τ knockdown.

We did not observe an rs7554511 INAVA genotype–dependent difference in 14-3-3τ recruitment to INAVA when immunoprecipitating equivalent levels of INAVA (data not shown), consistent with this being a noncoding variant that modulates expression rather than structure of INAVA. 14-3-3τ was also recruited to INAVA with TLR4 stimulation (Supplemental Figure 18A) and 14-3-3τ was required for optimal TLR4-induced cytokines (Supplemental Figure 18B). Therefore, upon NOD2 stimulation, INAVA assembles in a complex with proximal signaling molecules that participate in NOD2-induced outcomes.

To definitively establish the role of the 14-3-3 regions in INAVA in regulating INAVA-mediated outcomes, we generated INAVA constructs in which the serine required for 14-3-3 recruit-ment in each of the 3 putative 14-3-3 regions identified in INAVA (Figure 7B) was mutated to an alanine, alone and in combination. HEK293 cells did not express endogenous INAVA (Supplemental Figure 19A), such that we used these cells for our transfection studies. Each of the INAVA variants was expressed to equivalent levels in HEK293 cells (Supplemental Figure 19B). We first established that, similar to the endogenous INAVA and 14-3-3τ interactions we observed in primary human MDMs, upon MDP treatment of HEK293 cells transfected with NOD2 and WT INAVA, 14-3-3τ recruitment to INAVA increased and p-ERK was recruited to INAVA (Figure 7G). Importantly, mutation of the serine in each of the 14-3-3 recruitment regions in INAVA led to decreased 14-3-3τ and p-ERK recruitment to INAVA upon NOD2 stimulation (Figure 7G). The INAVA variant in which all three 14-3-3 recruitment regions were mutated demonstrated a greater impairment in 14-3-3τ and p-ERK recruitment (Figure 7G). Furthermore, the INAVA variants with mutations in each of the three 14-3-3 recruitment regions led to decreased NOD2-induced signaling in the pathways we found to be regulated by INAVA, with a decrease in the MAPK pathway as assessed by AP-1 luciferase activity, and in the NF-κB pathway as assessed by NF-κB luciferase activity (Figure 7H).

Finally, upon MDP treatment of NOD2-transfected cells, IL-6 secretion was enhanced by WT INAVA, but this enhancement was impaired by each of the 3 INAVA mutants in the 14-3-3 recruitment regions, and further impaired in the variant with mutation of all three 14-3-3 recruitment regions (Figure 7I). Therefore, the 14-3-3τ recruitment regions in INAVA are required for optimal association between INAVA and 14-3-3τ, and for PRR-induced recruitment of the signaling complex to INAVA, cellular signaling pathway activation, and cytokine secretion.

INAVA is required for optimal induction of bacterial clearance pathways and intracellular bacterial clearance. Impaired bacterial...
Figure 7. 14-3-3τ recruitment to INAVA contributes to optimal assembly of a signaling complex and to INAVA modulation of PRR-induced signaling and cytokine secretion. (A) MDMs were treated with 100 μg/ml MDP for 15 minutes. INAVA was immunoprecipitated and recruitment of NOD2, RIP2, and IRAK1 was assessed by Western blot. Equivalent expression for the respective proteins is shown in whole-cell lysates (WCLs). (B) Sequence alignments for putative 14-3-3 binding regions within INAVA from select species. (C) MDMs were treated with 100 μg/ml MDP for 15 minutes. INAVA was immunoprecipitated and recruitment of 14-3-3τ, p-ERK, ERK, p-p38, p38, and p-IκBα was assessed by Western blot. Equivalent expression for the respective proteins is shown in WCLs. Data are representative of n = 9 for 14-3-3τ, n = 9 for p-ERK, n = 4 for ERK, n = 3 for p-p38, n = 4 for p38, and n = 3 for p-IκBα. (D–F) MDMs were transfected with scrambled or 14-3-3τ siRNA. (D) Transfected MDMs were treated with 100 μg/ml MDP for 15 minutes. INAVA was immunoprecipitated and recruitment of 14-3-3τ and p-ERK was assessed by Western blot. Representative Western blot for 1 of 6, and 1 of 4 individuals, respectively. (E) Transfected cells were treated with 100 μg/ml MDP for 15 minutes and assessed for ERK activation by phospho-flow. Fold p-ERK induction was normalized to untreated, scrambled siRNA–transfected cells + SEM (n = 8). Similar results were observed in an additional n = 8. (F) Transfected cells were treated with 100 μg/ml MDP for 24 hours. Mean cytokines + SEM (n = 4). Similar results were observed in an additional n = 8. (G) HEK293 cells were transfected with NOD2 + the indicated HA-INAVA variants, and then treated with 100 μg/ml MDP for 15 minutes. Mean cytokines + SEM (n = 6). (H and I) HEK293 cells were transfected with NOD2, a Renilla reporter, AP-1 or NF-κB luciferase reporters, and empty vector or the indicated INAVA variants. (H) Transfected cells were treated with 100 μg/ml MDP for 6 hours and activation of AP-1 and NF-κB luciferase reporters was assessed and normalized to Renilla. Mean + SEM for triplicates. Representative of 3 independent experiments. (I) Transfected cells were treated with 100 μg/ml MDP for 24 hours and secreted IL-6 was assessed + SEM for triplicates. Representative of 3 independent experiments. Tx, treatment. *P < 0.05; †P < 0.01; §P < 0.001; ‡P < 1 × 10−4; ¶P < 1 × 10−5; determined by 2-tailed Student’s t test. IP, immunoprecipitated; IB, immunoblotted.
clearance can increase the risk for IBD (5, 36–38), and PRR-initiated pathways contribute to intracellular bacterial clearance (2). As the rs7554511 IBD risk variant leads to reduced INAVA expression and reduced PRR-induced signaling and cytokines, we questioned if INAVA was required for optimal macrophage-mediated bacterial clearance. Prolonged stimulation of macrophages through ATG5 was also decreased (Figure 9C). Each of these proteins was required for optimal AIEC clearance (Supplemental Figure 20, A and B). We also observed a requirement for INAVA in the NOD2-induced autophagy observed in MDMs (Figure 9D). This was associated with an INAVA-dependent role for induction of the autophagy-associated gene, ATG5, whereas induction of ATG10 and immunity-related GTPase M (IRGM) expression was not INAVA dependent (Figure 9E). We verified that ATG5 was required for optimal NOD2-induced autophagy (Supplemental Figure 20, C and D) and bacterial clearance (Supplemental Figure 20, C and D) and bacterial clearance (Supplemental Figure 20, C and D).
NOS2 (Figure 10B), as well as the induction of LC3II and ATG5 (Figure 10C) was increased in MDMs from rs7554511 AA carriers compared with CC carriers. Heterozygotes demonstrated an intermediate phenotype. Importantly, knocking down INAVA expression in AA carriers to the levels seen in CC carriers (Supplemental Figure 8A) reduced each of these outcomes to the levels of CC carriers (Figure 10, D–F). Conversely, increasing the INAVA expression in CC carriers to the levels seen in AA carriers (Supplemental Figure 9A) increased each of the bacterial clearance pathways to the levels seen in AA carriers (Figure 10, G–I).

INAVA regulates a broad range of NOD2-induced transcripts.

As INAVA regulates both NOD2-induced MAPK and NF-κB pathways, and these signaling pathways in turn regulate a broad range of NOD2-induced transcripts, we postulated that in addition to its regulation of PRR-induced cytokines and the select antimicrobial-associated pathways we had examined, INAVA would regulate a broad spectrum of NOD2-induced transcripts. We focused on the NOD2-upregulated transcripts identified 20E). To clearly address the role of these pathways downstream of INAVA upon NOD2 stimulation, we restored p47phox and p67phox, the NADPH oxidase members showing the strongest contribution to AIEC clearance (Supplemental Figure 20B), in INAVA-deficient MDMs (Supplemental Figure 20F). This rescued ROS in INAVA-deficient cells (Supplemental Figure 20G) and partially rescued intracellular bacterial clearance (Figure 9F). Restoring NOS2 in INAVA-deficient MDMs (Supplemental Figure 20H) similarly partially rescued bacterial clearance (Figure 9F). Restoring ATG5 expression in INAVA-deficient macrophages (Supplemental Figure 20I) rescued autophagy (Supplemental Figure 20J) and partially rescued bacterial clearance (Figure 9F). Restoring ROS, RNS, and autophagy pathways in combination in INAVA-deficient MDMs fully rescued bacterial clearance, highlighting cooperation between these pathways (Figure 9F).

Consistent with the INAVA genotype–dependent regulation of bacterial killing, NOD2-mediated induction of ROS and the NAPDH oxidase subunits p47phox and p67phox (Figure 10A), NOS2 (Figure 10B), as well as the induction of LC3II and ATG5 (Figure 10C) was increased in MDMs from rs7554511 AA carriers compared with CC carriers. Heterozygotes demonstrated an intermediate phenotype. Importantly, knocking down INAVA expression in AA carriers to the levels seen in CC carriers (Supplemental Figure 8A) reduced each of these outcomes to the levels of CC carriers (Figure 10, D–F). Conversely, increasing the INAVA expression in CC carriers to the levels seen in AA carriers (Supplemental Figure 9A) increased each of the bacterial clearance pathways to the levels seen in AA carriers (Figure 10, G–I).

INAVA regulates a broad range of NOD2-induced transcripts. As INAVA regulates both NOD2-induced MAPK and NF-κB pathways, and these signaling pathways in turn regulate a broad range of NOD2-induced transcripts, we postulated that in addition to its regulation of PRR-induced cytokines and the select antimicrobial-associated pathways we had examined, INAVA would regulate a broad spectrum of NOD2-induced transcripts. We focused on the NOD2-upregulated transcripts identified...
A subset of NOD2-induced transcripts was not upregulated with dectin stimulation (Supplemental Figure 21A). However, we selected transcripts previously reported to be regulated by dectin (42), and found that dectin-induced transcripts were intact with INAVA knockdown (Supplemental Figure 21D), including transcripts that were also induced upon NOD2 stimulation (Supplemental Figure 21C). Therefore, consistent with the INAVA regulation of broad NOD2-induced signaling pathways, INAVA modulates a broad range of NOD2-induced transcripts.

Discussion
In this study, we identify roles for the IBD-associated gene INAVA that encodes for a previously undescribed protein; we found that INAVA is expressed in human peripheral and intestinal myeloid-derived cells. INAVA increases PRR-induced signaling, cytokine secretion, bacterial clearance, and broad transcriptional responses in human macrophages. We identified that INAVA has three 14-3-3 binding regions through which 14-3-3\(\tau\) is recruited, thereby leading to the assembly of a signaling complex upon PRR stimulation that includes p-ERK, p-p38, and p-I\(\kappa\)B\(\alpha\), which, in turn, amplifies PRR-induced signaling and cytokine secretion (Figure 11). Consistent with the roles that we now identify for INAVA in PRR-induced signaling, the lower INAVA expression in rs7554511 C risk carriers is associated with decreased NOD2-induced signaling, cytokine secretion, and bacterial clearance.

We identify that at least one mechanism contributing to the lower INAVA expression in rs7554511 C risk carriers is a decrease in the transcriptional activity mediated directly by intron 6 where the variant is located. In particular, mutating the A variant to the C variant significantly attenuates intron 6–mediated transcriptional activity. This is likely attributable to a decreased cooperative effect between multiple transcription factors. We identified that at least one of the transcription factors contributing to intron 6–mediated transcriptional activity is TBP, and that TBP-induced transcription is less in the rs7554511 C variant. It is also possible that there are additional polymorphisms in the INAVA region in LD with rs7554511 that affect regulatory regions that also modulate INAVA expression, such that the rs7554511 genotype–dependent regulation of INAVA is likely multifactorial.

Decreased cytokines and PRR-initiated outcomes (9–11, 17, 18, 43, 44) and impaired bacterial clearance have been implicated in subsets of IBD patients (5, 36–38, 45–47). Furthermore, genetic perturbations in pathways critical for bacterial clearance have through microarray (41), and found that the upregulation of these transcripts was impaired with INAVA knockdown (Supplemental Figure 21A). To demonstrate the MAPK/NF-\(\kappa\)B dependency of these transcripts, we examined the same transcripts upon NOD2 stimulation while inhibiting the MAPK and NF-\(\kappa\)B pathways and found that their upregulation was similarly impaired (Supplemental Figure 21A). We ensured the cells were viable under these conditions (Supplemental Figure 21B). As a control for specificity of INAVA effects, we examined dectin-induced transcripts, as we had found that dectin-induced antiinflammatory mediators did not depend on INAVA (Supplemental Figure 21B).
One such association occurs between 14-3-3 isoforms to associate with molecules that affect PRR signaling pathways downstream of PRRs (31–33). 14-3-3 isoforms have been shown have identified a role for 14-3-3 proteins in modulating signaling (C1orf106) in a yeast 2-hybrid system (50). Only a few studies τ proteins upon PRR stimulation, including NOD2, RIP2, IRAK1, INAVA, and 14-3-3τ, may result in consequences to INAVA function through alternative mechanisms. [49] that may result in consequences to INAVA function through alternative mechanisms.

The decreased responses through PRR-initiated pathways in INAVA risk carriers may also contribute to impaired recruitment of immune cells and other critical innate functions, including innate-instructed adaptive immune outcomes. Moreover, INAVA may contribute to functions in myeloid-derived cells in addition to those initiated by PRR stimulation, as well as to functions by additional cell subsets. We did not observe that expression of other genes in the region was modulated in an rs7554511 genotype–dependent manner in myeloid-derived cells or that these genes were able to modulate NOD2-induced cytokinase. However, it remains possible that a subset of these other genes, or genes beyond the 500-kb distance from the rs7554511 polymorphism that we examined, may regulate other PRR-dependent or PRR-independent functions in myeloid-derived cells or alternative functions in nonmyeloid cell subsets in a genotype-dependent manner. Moreover, we focus on a common risk variant in INAVA; there are rare INAVA variants (49) that may result in consequences to INAVA function through alternative mechanisms.

We identified that INAVA assembled in a complex with several proteins upon PRR stimulation, including NOD2, RIP2, IRAK1, and 14-3-3τ. A prior study found that 14-3-3ε interacts with INAVA (C1orf106) in a yeast 2-hybrid system (50). Only a few studies have identified a role for 14-3-3 proteins in modulating signaling downstream of PRRs (31–33). 14-3-3 isoforms have been shown to associate with molecules that affect PRR signaling pathways (50, 51). One such association occurs between 14-3-3 isoforms ε, ζ, INAVA expression threshold required for distinct immunological outcomes. Expression/function threshold differences have been observed for various molecules (54, 55).

Our findings define a critical role for the newly defined protein INAVA in processes crucial for intestinal immune homeostasis, including the regulation outcomes downstream of a broad range of PRRs in human macrophages. We further identify that in MDMs from INAVA rs7554511 C risk carriers demonstrate lower INAVA expression, and consistently, decreased MAPK and NF-κB signaling, cytokine secretion, and bacterial clearance.

**Methods**

*Patient recruitment and genotyping.* Informed consent was obtained per protocol approved by the IRB at Yale University and healthy controls were recruited for the studies. We performed genotyping by TaqMan genotyping (Applied Biosystems) or utilizing the Sequenom platform (Sequenom Inc.).

*MDM cell isolation and cell culture.* Monocytes were purified from human peripheral blood mononuclear cells by positive CD14 selection (Miltenyi Biotec) or adhesion, tested for purity, and cultured with 10 ng/ml M-CSF (Shenandoah Biotechnology) for MDM differentiation (20). Cultured myeloid cells were treated with MDP (Bachem), PamCys (EMD Millipore), lipid A (Peptides International), polyI:C, flagellin, CL097, or CpG DNA (all Invivogen). Supernatants were assayed for TNF, IL-6, IL-8, IL-10 (all BD Biosciences), IL-12, or IL-1β (both eBioscience) by ELISA.
Intestinal lamina propria cell isolation. Intestinal lamina propria cells were isolated from colonic resection specimens from uninvolved intestine in 7 non-IBD patients undergoing surgery for diverticular disease or colonic cancer (9).

mRNA expression analysis. RNA was isolated, reverse transcribed, and quantitative PCR performed on the ABI Prism 7000 (Applied Biosystems) using primer sequences as per Supplemental Table 1. Samples were normalized to GAPDH.

Transfection of siRNAs and DNA vectors. Pooled siRNA containing 4 different siRNAs at 100 nM or indicated concentrations for each INAVA (Clontech06), 14-3-3-α, TBP, or scrambled siRNA (SMARTpool, Dharmacon), or of vectors expressing ATG5 (Addgene plasmid 24922; deposited by Toren Finkel; see ref. 56), NOS2 (gift of Tony Eissa; see ref. 57), p47phox and p67phox (gifts of Celine DerMardirian; see ref. 58), or pEGFP-C1-TBP (Clontech plasmid 26674; deposited by Sui Huang; see ref. 59) were transfected into MDMs using a Nucleofector Kit (Amaxa) for 48 hours. INAVA (Clontech06) was subcloned from BCI06877 (ORD3016) plasmid (Transomic) into pcDNA3.0 along with an HA tag. HA-INAVA S246A, HA-S340A, and HA-S616A, alone and in combination, were generated through site-directed mutagenesis (QuickChange Lightning Kit; Agilent Technologies). INAVA intron 6 containing the rs7554511 A SNP was subcloned into the pGL4.17 vector (Promega). Site-directed mutagenesis was used to generate the rs7554511 C variant. For INAVA transfection assays, 800 ng of each HA-INAVA construct was transfected along with 50 ng NOD2 ± 50 ng pNF-κB luciferase or pAP-1-luciferase (both Clontech), and 15 ng pRLCMV (Promega) as a Renilla normalization control. For transfection factor transfections, 50 ng of each INAVA intron 6 construct, 800 ng pEGFP-C1-TBP, and 15 ng pRLCMV as a Renilla normalization control was transfected into cells. Numbering of the nucleotides and amino acids was according to the Genbank accession number BCI06877.2.

Protein expression analysis. INAVA was immunoprecipitated from MDMs with antibodies against INAVA (Clontech06) (Abcam, ab121945) or from transfected HEK293 cells with antibodies against HA (Abcam, ab137838) bound to protein A or protein G Sepharose (EMD Millipore). Immunoprecipitates were blotted for NOD2 (Cayman Chemicals, 160777), RIP2 (BD Biosciences, clone 25/RIG-G), 14-3-3-α (catalog 9242), or IRAK1 (clone D517G) (all Cell Signaling Technology) and p38 (Santa Cruz Biotechnology, clone A-12) (20). GAPDH (EMD Millipore) or the respective protein in whole-cell lysates served as the loading control.

Phosphoprotein induction was determined using Alexa Fluor 647-, phycoerythrin-, Alexa Fluor 488-, or biotin-labeled antibodies against p-ERK (clone D13.14.4E), p-p38 (clone 3D7), p-JNK (clone G9), or p-IκBα (clone 14D4) (all Cell Signaling Technology) by flow cytometry. Permeabilized cells were assessed for protein expression by flow cytometry with anti-INAVA (anti-Clorf016), anti-ATG5 (clone EPR1755(2)) (both Abcam), anti-NOS2 (catalog 2977), anti-β3G1 (catalog 2775) (both Cell Signaling Technology), anti-p47phox (clone A-7), and anti-p67phox (clone D-6) (both Santa Cruz Biotechnology). Isotype controls matching the specific antibody were used in the flow cytometry.

Intracellular ROS measurement. ROS was measured by flow cytometry using 10 μM 2′,7′-dichlorodihydrofluorescein diacetate (H_DCFDA) (Invitrogen).

Intracellular bacterial clearance. Following treatment, MDMs were infected in triplicate for 1 hour with AIEC strain LF82 (a gift from Emiko Mizoguchi, Kurume University, Kurume, Japan) at 10:1 MOI, S. aureus at 1:1 MOI or E. faecalis at 1:1 MOI, washed 3 times with PBS, and incubated in HBSS medium containing 50 μg/ml gentamicin for an additional hour. Cells were washed, lysed with 1% Triton X-100 (Sigma-Aldrich), and plated on MacConkey or LB agar.

 Luciferase activity. Cells were lysed, assayed for luciferase, and normalized to Renilla activity (Promega) according to the manufacturer’s instructions and using the Synergy 2 (BioTek).

Statistics. Significance was assessed using a 2-tailed Student’s t test. To keep cytokines on the same axis, a multiplier was applied for the higher levels of IL-8 as shown in the Figure keys. P less than 0.05 was considered significant.

Author contributions

JY, MH, and CA were involved in research design, conducting experiments, analyzing data, and writing the manuscript.

Acknowledgments

This work was supported by the NIH grants DK099097, DK062422, and DK-P30-34989, The Broad Foundation, and The Crohn’s and Colitis Foundation of America. We thank Tony Eissa, Celine DerMardirian, and Emiko Mizoguchi for reagents.

Address correspondence to: Clara Abraham, Department of Internal Medicine, Section of Digestive Diseases, 333 Cedar Street (LMP 1080), New Haven, Connecticut 06520, USA. Phone: 203.785.5610; E-mail: clara.abraham@yale.edu.

The Journal of Clinical Investigation


